An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Saved in:
| Title: | An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. |
|---|---|
| Authors: | Liu J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: joyce_liu@dfci.harvard.edu., Burris H; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA., Wang JS; Hematologic Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA., Barroilhet L; Department of Obstetrics and Gynecology, University of Wisconsin-Madison, Madison, WI, USA., Gutierrez M; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA., Wang Y; Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA., Vaze A; Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA., Commerford R; Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA., Royer-Joo S; Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA., Choeurng V; Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA., Humke E; Early Clinical Development, Genentech, Inc, South San Francisco, CA, USA., Moore K; University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. |
| Source: | Gynecologic oncology [Gynecol Oncol] 2021 Dec; Vol. 163 (3), pp. 473-480. Date of Electronic Publication: 2021 Oct 06. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
